HBM HLDGS LTD DL-000025 (6XY) - Total Liabilities
Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) has total liabilities worth €133.14 Million EUR (≈ $155.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is HBM HLDGS LTD DL-000025's working capital to evaluate short-term liquidity relative to the company's equity base.
HBM HLDGS LTD DL-000025 - Total Liabilities Trend (2021–2025)
This chart illustrates how HBM HLDGS LTD DL-000025's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 6XY asset base.
HBM HLDGS LTD DL-000025 Competitors by Total Liabilities
The table below lists competitors of HBM HLDGS LTD DL-000025 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ramsay Generale De Sante
PA:GDS
|
France | €5.41 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
India | Rs2.29 Billion |
|
Streamax Technology Co Ltd
SHE:002970
|
China | CN¥1.29 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
China | CN¥1.47 Billion |
|
Hotel101 Global Holdings Corp. Class A Ordinary Shares
NASDAQ:HBNB
|
USA | $135.19 Million |
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
USA | $1.02 Billion |
|
Talant Optronics (Suzhou) Co. Ltd.
SHE:301045
|
China | CN¥298.09 Million |
|
Tamboran Resources Corporation
NYSE:TBN
|
USA | $125.48 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down HBM HLDGS LTD DL-000025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of HBM HLDGS LTD DL-000025 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HBM HLDGS LTD DL-000025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HBM HLDGS LTD DL-000025 (2021–2025)
The table below shows the annual total liabilities of HBM HLDGS LTD DL-000025 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €133.14 Million ≈ $155.66 Million |
+46.37% |
| 2024-12-31 | €90.96 Million ≈ $106.34 Million |
-16.43% |
| 2023-12-31 | €108.85 Million ≈ $127.26 Million |
-22.04% |
| 2022-12-31 | €139.62 Million ≈ $163.23 Million |
+134.87% |
| 2021-12-31 | €59.45 Million ≈ $69.50 Million |
-- |
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more